Boston Scientific misses by $0.01, beats on revs; guides Q2 EPS in-line, revs in-line; reaffirms FY17 EPS guidance, guides FY17 revs in-line (25.97)
- Reports Q1 (Mar) earnings of $0.29 per share, $0.01 worse than the Capital IQ Consensus of $0.30; revenues rose 10.0% year/year to $2.16 bln vs the $2.08 bln Capital IQ Consensus.
- Co issues in-line guidance for Q2, sees EPS of $0.30-0.32 vs. $0.31 Capital IQ Consensus Estimate; sees Q2 revs of $2.185-2.215 bln vs. $2.22 bln Capital IQ Consensus Estimate.
- Co issues guidance for FY17, reaffirms EPS of $1.22-1.26 vs. $1.24 Capital IQ Consensus Estimate; sees FY17 revs of $8.80-8.90 bln vs. $8.79 bln Capital IQ Consensus Estimate, up from prior guidance of 8.675 to $8.875 bln.